Cargando…

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Detalles Bibliográficos
Autores principales:	Marcec, Robert, Dodig, Vinko Michael, Likic, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673087/ https://www.ncbi.nlm.nih.gov/pubmed/36403698 http://dx.doi.org/10.1016/j.jinf.2022.11.011

Ejemplares similares

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?
por: Marcec, Robert, et al.
Publicado: (2022)

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?
por: Marčec, Robert, et al.
Publicado: (2021)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

Will vaccination refusal prolong the war on SARS-CoV-2?
por: Marcec, Robert, et al.
Publicado: (2020)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data
por: Brnic, Stjepan, et al.
Publicado: (2023)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Fluvoxamine Plays an Integral Role in the Alteration of Sexual Behavioral Pattern more in Females than Males
por: Santra, Ranjita
Publicado: (2012)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Letter to editor regarding “piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2”
por: Tosar, Juan Pablo
Publicado: (2023)

Response to the letter to editor regarding “piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2”
por: Wang, Qianqian, et al.
Publicado: (2023)

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
por: Papadopoulos, Konstantinos, et al.
Publicado: (2023)

Chronic disease: Working together
por: Laidmäe, Virve-Ines
Publicado: (2013)

Retinoblastoma: Making a Difference Together
por: Davis, Mary Elizabeth
Publicado: (2017)

Role of flow preference in decision making regarding the use of Blalock-Taussig shunt
por: Salihoğlu, Ece
Publicado: (2018)

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
por: Reis, Gilmar, et al.
Publicado: (2022)

Concerns regarding result analysis and the corresponding risk of pulmonary embolism severity and in-hospital mortality
por: Ahmed, H Shafeeq
Publicado: (2022)

Regarding the Article: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
por: LEÓN-ROSALES, SAMUEL PONCE DE, et al.
Publicado: (2022)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Letter to the Editor regarding “The relationship between serum vitamin D and fracture risk in the elderly: a meta-analysis”
por: Li, Qiujiang, et al.
Publicado: (2020)

Author's Response to Letters to the Editor regarding “Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies”
por: Park, Robert M.
Publicado: (2022)

Response to: Regarding the Article: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
por: BONILLA, CÉSAR RAÚL GONZALEZ
Publicado: (2022)

When doctors as well as bureaucrats work together!
por: Gupta, Harish, et al.
Publicado: (2022)

Letter to the Editor regarding Meta-analysis of the efficacy of gabapentin: a response
por: Masoud, Ahmed Taher, et al.
Publicado: (2022)

In reply to the letter to the editor regarding “The Relationship Between Serum Vitamin D and Fracture Risk in the Elderly: A Meta-Analysis”
por: Wang, Ning, et al.
Publicado: (2020)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

The experience of Careggi Hospital (Florence) regarding Not Received Samples (NRS): a pilot study of Risk Management in the Clinical Laboratory
por: TROIANO, G., et al.
Publicado: (2020)

Antiplatelet Agents in Sepsis—Putting it all together: A Call to Action
por: Tiwari, Nishant R, et al.
Publicado: (2020)

Regarding: “Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis”
por: Cai, Jianghui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gemppcj3f1bp5c9p07hr21tled